Literature DB >> 18254773

Expression of the cell-cell adhesion molecule beta-catenin in colorectal carcinomas and their metastases.

A Buhmeida1, A Elzagheid, A Algars, Y Collan, K Syrjänen, S Pyrhönen.   

Abstract

To study the dynamic events leading to impaired cell-cell adhesion upon transition to the invasive phenotype of colorectal cancer (CRC), we examined three distinct beta-catenin expression patterns (membranous, cytoplasmic, and nuclear) in the paired samples of the primary tumours (P) and their metastatic lesions (M). beta-catenin expression was detected by immunohistochemistry (IHC) in 33 pairs of the primary CRC and their metastases. In a pair-wise (P-M) comparison, the membranous index (MI) was significantly different between P and M (p=0.036, Wilcoxon Signed-Ranks test), while cytoplasmic index (CI) and nuclear index (NI) values did not significantly deviate between P and M. MI in primary tumours was inversely related to the patient's age (p=0.04) and tumour grade (p=0.03), while patients with low MI in M had a high rate of metastasis at diagnosis (p=0.06). CI in P was lower in patients with LN involvement (p=0.02) and in advanced tumour stage (p=0.002). Tumours of the ascending colon had the highest CI in their M (p=0.04). Interestingly, high MI of the M lesions was a significant predictor of favourable overall survival (OS) in univariate (Kaplan-Meier) survival analysis (p=0.035). In conclusion, significant aberrations in beta-catenin expression probably take place in CRC cells during the development of metastatic phenotype, but a change from membrane expression to cytoplamic and/or nuclear expression is not a prerequisite for metastasis in all cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18254773     DOI: 10.1111/j.1600-0463.2008.00754.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

1.  A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth.

Authors:  Claudia Bocca; Francesca Bozzo; Monica Ievolella; Antonella Miglietta
Journal:  Mol Cell Biochem       Date:  2011-10-15       Impact factor: 3.396

2.  Investigation of β-catenin and E-cadherin expression in Dukes B2 stage colorectal cancer with tissue microarray method. Is it a marker of metastatic potential in rectal cancer?

Authors:  László Tóth; Csilla András; Csaba Molnár; Miklós Tanyi; Zoltán Csiki; Péter Molnár; János Szántó
Journal:  Pathol Oncol Res       Date:  2012-04       Impact factor: 3.201

3.  Leptin Protein Expression and Promoter Methylation in Ovarian Cancer: A Strong Prognostic Value with Theranostic Promises.

Authors:  Mourad Assidi; Fatimah M Yahya; Maryam H Al-Zahrani; Razan Elkhatib; Ali Zari; Aisha Elaimi; Jaudah Al-Maghrabi; Ashraf Dallol; Abdelbaset Buhmeida; Muhammad Abu-Elmagd
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

4.  Prognostic value of E-Cadherin and its tumor suppressor role in Saudi women with advanced epithelial ovarian cancer.

Authors:  Mourad Assidi; Mohammad Alam Jafri; Muhammad Abu-Elmagd; Peter N Pushparaj; Salina Saddick; Safia Messaoudi; Heba Alkhatabi; Jaudah Al-Maghrabi; Nisreen Anfinan; Maram Sait; Abdelfatteh El Omri; Hesham Sait; Hussain Basalamah; Abdelbaset Buhmeida; Khalid Sait
Journal:  Libyan J Med       Date:  2021-12       Impact factor: 1.657

5.  The Prognostic Value of the Developmental Gene FZD6 in Young Saudi Breast Cancer Patients: A Biomarkers Discovery and Cancer Inducers OncoScreen Approach.

Authors:  Mourad Assidi; Abdelbaset Buhmeida; Maryam H Al-Zahrani; Jaudah Al-Maghrabi; Mahmood Rasool; Muhammad I Naseer; Heba Alkhatabi; Abdulmajeed F Alrefaei; Ali Zari; Razan Elkhatib; Adel Abuzenadah; Peter N Pushparaj; Muhammad Abu-Elmagd
Journal:  Front Mol Biosci       Date:  2022-02-14

6.  Evaluation of the correlation of KAI1/CD82, CD44, MMP7 and β-catenin in the prediction of prognosis and metastasis in colorectal carcinoma.

Authors:  Qiong Wu; Yan Yang; Shiwu Wu; Wanyun Li; Na Zhang; Xiuqin Dong; Yurong Ou
Journal:  Diagn Pathol       Date:  2015-09-25       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.